About TOT BIOPHARM-B Company

Dongyao Pharmaceutical is a biopharmaceutical company developing drugs that have entered the clinical stage, focusing on the development and commercialization of innovative oncology drugs and therapies. The company strives to become a leading oncology treatment brand worthy of the trust of medical professionals, patients and their families. Currently, the company has a drug portfolio under development for various cancers, including monoclonal antibody drugs, antibody conjugated drugs (ADCs), oncolytic virus drugs, and special anti-tumor drugs (such as liposomal drugs). Since its establishment in 2009, the company has established a comprehensive platform integrating drug discovery, product development, quality management, pre-clinical and clinical development, commercial production and marketing, providing flexibility and expandability for the company to develop business in the innovative pharmaceutical industry value chain. The company has established three comprehensive technology platforms, including technical platforms for therapeutic monoclonal antibodies and antibody-conjugated drugs (ADCs), therapeutic technology platforms based on genetic engineering, and innovative drug delivery technology platforms. The therapeutic monoclonal antibody and ADC drug technology platform integrates the company's R&D and production capabilities to enable the company to develop a series of antibody drugs and ADCs; the genetic engineering-based treatment technology platform integrates anti-tumor immunotherapy, gene therapy and viral therapy to carry out the development and production of recombinant virus vector systems for tumor targets; the innovative delivery technology platform covers advanced targeted liposome delivery systems. The system has key embedding technology for hydrophobic and hydrophilic compounds, which can avoid the decomposition of the embedded composition and release the embedded composition at the intended target site. Using the technology platform described above, Dongyao Pharmaceutical has developed a series of products, established a strong product pipeline, and continued to promote pre-clinical and clinical development of related drugs under development in accordance with this. With the company's comprehensive industrial value chain capabilities, Dongyao Pharmaceutical has established an open platform business model, cooperated with third parties at different stages of the industrial value chain, complements different industry participants, and reached various forms of cooperation. Dongyao Pharmaceutical has formed an experienced senior management team with deep expertise in cancer treatment. Team members' expertise includes various fields such as preclinical research, clinical development, production, quality control and assurance, and commercialization. The technology covers monoclonal antibody drugs, ADC drugs, oncolytic virus drugs and special small molecule antitumor drugs.